Comprehensive Guide to Paclieva 30mg Injection: Global Export & Distribution by Ernest Oncology

In the global fight against cancer, access to reliable, high-quality chemotherapy medications is vital. At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Paclieva 30mg Injection to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

This comprehensive guide covers the medical profile, mechanisms, uses, and an extensive list of SEO keywords designed to boost the online visibility of B2B pharmaceutical suppliers.

1. What is Paclieva 30mg Injection?

Paclieva 30mg Injection contains the active pharmaceutical ingredient Paclitaxel, which belongs to the taxane class of anti-microtubule agents. It is a frontline chemotherapy medication used to disrupt the lifecycle of cancer cells, primarily those that divide rapidly.

Key Product Details:

• Composition: Paclitaxel (30 mg/vial).

• Therapeutic Class: Anti-cancer / Chemotherapeutic agent.

• Chemical/Action Class: Antimicrotubule agent (Taxanes derivative).

• Dosage Form: Concentrate for solution for intravenous (IV) infusion.

2. Mechanism of Action

Paclieva 30mg works by targeting the structural framework of cancer cells. Here is how it functions at the cellular level:

• Microtubule Stabilization: Microtubules are essential for cell division and the structural integrity of cells. Paclitaxel binds reversibly to the beta-tubulin subunits, locking them together.

• Mitotic Arrest: By preventing the microtubules from disassembling, Paclieva stops the cell from completing the mitotic phase of the cell cycle.

• Apoptosis: The inability to complete division triggers cell death (apoptosis), selectively killing rapidly dividing malignant cells.

3. Therapeutic Indications and Uses

Paclieva 30mg is prescribed for several forms of cancer, either as a standalone treatment or as part of a multi-drug chemotherapy regimen:

• Breast Cancer: Used for early-stage post-surgery treatment or metastatic breast cancer, helping to alleviate symptoms such as lumps, and inhibiting the growth of malignant cells.

• Ovarian Cancer: Prescribed as a first-line treatment or secondary treatment for advanced ovarian cancer.

• Non-Small Cell Lung Cancer (NSCLC): Administered alongside platinum-based regimens to reduce tumor sizes and improve lung function.

• Pancreatic Cancer: Helps control the progression of pancreatic cancer and mitigates symptoms like severe weight loss and loss of appetite.

• AIDS-Related Kaposi's Sarcoma: Inhibits the growth and spread of malignant skin lesions in immunocompromised patients.

4. Administration, Dosage, and Storage Guidelines

Administration & Dosage

• Route: Administered exclusively via intravenous (IV) infusion by a qualified healthcare professional.

• Protocol: The dosage depends on the patient's Body Surface Area (BSA), the specific cancer being treated, and the chemotherapy protocol.

• Pre-medication: Patients are often given medications beforehand (like corticosteroids or antihistamines) to prevent severe allergic reactions.

Storage Conditions

• Store the vials in a refrigerator (between 2°C and 8°C).

• Protect from direct light.

• Do not freeze.

5. Potential Side Effects & Safety Information

Like all potent chemotherapeutic agents, Paclieva 30mg carries notable side effects and contraindications:

• Common Side Effects: Nausea, vomiting, diarrhea, hair loss, fatigue, joint/muscle pain, and burning/tingling of the hands or feet (peripheral neuropathy).

• Severe Risks: Anemia, low white blood cell count (neutropenia—increasing the risk of infections), and serious allergic reactions.

• Contraindications: Highly unsafe during pregnancy and breastfeeding, as it can cause fetal harm. Patients with severe liver disorders or uncontrolled infections must consult their healthcare provider before use.

•